 7. Patients receiving any systemic chemotherapy, radiotherapy except for palliative reasons, within 2 weeks from the last dose prior to study treatment or a longer period depending on the defined characteristics of the agents used. The patient can receive a stable dose of bisphosphonates or denosumab for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with study drug. 